Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ITRM 
Iterum Therapeutics PLC (ITRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ITRM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.99% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.40M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 2.82 | 52 Weeks Range 0.81 - 3.02 | Updated Date 06/29/2025 |
52 Weeks Range 0.81 - 3.02 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.6% | Return on Equity (TTM) -555.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 59569000 | Price to Sales(TTM) 1349.79 |
Enterprise Value 59569000 | Price to Sales(TTM) 1349.79 | ||
Enterprise Value to Revenue 105.22 | Enterprise Value to EBITDA 0.55 | Shares Outstanding 40000000 | Shares Floating 39254000 |
Shares Outstanding 40000000 | Shares Floating 39254000 | ||
Percent Insiders 1.03 | Percent Institutions 6.4 |
Analyst Ratings
Rating 1 | Target Price 7 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Iterum Therapeutics PLC
Company Overview
History and Background
Iterum Therapeutics PLC is a pharmaceutical company focused on developing and commercializing anti-infectives to treat multi-drug resistant infections. Founded in 2014, it has primarily focused on developing sulopenem for oral and IV administration.
Core Business Areas
- Anti-Infectives Development: Focused on developing and commercializing sulopenem to combat multi-drug resistant infections. Currently, it is not FDA approved and under review.
Leadership and Structure
Core team includes Corey Fishman (CEO) and Richard Betts (CMO). The company has a board of directors and operates with a functional organizational structure centered around clinical development, regulatory affairs, and commercial preparation.
Top Products and Market Share
Key Offerings
- Sulopenem: Sulopenem is a novel penem anti-infective with potent in vitro activity against Gram-negative, Gram-positive and anaerobic bacteria resistant to other antibiotics. It is designed to treat uncomplicated urinary tract infections (uUTIs) in patients with quinolone-resistant bacteria. This product is not yet FDA approved. Competitors include generic antibiotics used for uUTIs (e.g., ciprofloxacin, levofloxacin), as well as newer antibiotics like cefiderocol (FETROJA) by Shionogi and imipenem/cilastatin/relebactam (RECARBRIO) by Merck.
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of antibiotic-resistant bacteria and the need for new treatment options. There is a strong emphasis on developing drugs to combat serious infections, particularly those resistant to existing therapies.
Positioning
Iterum Therapeutics is positioned as a company seeking to provide a novel oral and IV penem antibiotic to combat resistant infections. Their competitive advantage would be the potential for both oral and IV administration in an outpatient setting.
Total Addressable Market (TAM)
The global urinary tract infection treatment market size was valued at $9.5 billion in 2022 and is projected to reach $14.4 billion by 2032, growing at a CAGR of 4.3% from 2023 to 2032. Iterum's positioning is based on targeting a subset of this market: quinolone-resistant uUTIs. The value of that market segment is hard to quantify.
Upturn SWOT Analysis
Strengths
- Novel oral and IV formulation of sulopenem
- Potential for outpatient treatment of resistant infections
- Addresses a growing need for new antibiotics
Weaknesses
- No FDA approval yet
- High cash burn rate
- Reliance on single product candidate (sulopenem)
- Limited commercial infrastructure
Opportunities
- Potential for FDA approval and commercialization of sulopenem
- Partnerships with larger pharmaceutical companies for distribution
- Expansion of sulopenem's use to other indications
Threats
- Failure to obtain FDA approval
- Competition from other antibiotics
- Generic erosion of sulopenem after market exclusivity expires
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- SHPG
- MRK
Competitive Landscape
Iterum is at a significant disadvantage compared to established players like Shionogi and Merck due to its lack of FDA-approved products and limited resources.
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth due to pre-revenue status.
Future Projections: Future growth is highly dependent on FDA approval and successful commercialization of sulopenem. Analyst projections are speculative at this point.
Recent Initiatives: Focusing on resubmitting NDA for sulopenem to FDA.
Summary
Iterum Therapeutics is a high-risk, high-reward pharmaceutical company. Its future hinges on FDA approval of sulopenem. The company is currently struggling financially. Failure to obtain approval or secure additional funding will significantly harm its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iterum Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-05-25 | President, CEO & Director Mr. Corey N. Fishman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.iterumtx.com |
Full time employees 9 | Website https://www.iterumtx.com | ||
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.